Antibody response to seasonal influenza vaccination in multiple sclerosis patients receiving immunomodulatory therapy

European Journal of Neurology Dec 08, 2017

Olberg HK, et al. - The authors performed this study to examine the influence of immunomodulatory therapies on the antibody response and seroprotection rates in multiple sclerosis (MS) patients immunized with seasonal influenza vaccine in 2012/2013 compared to healthy controls. They proposed that in cases of insufficient protection, MS patients receiving fingolimod or natalizumab ought to be considered for a second dose of the vaccine. The outcomes further showed that new immunomodulatory treatment regimens needed to be systematically assessed for their influence on influenza-specific vaccine responses.
Go to Original

Sign-up to continue reading. It is free & takes less than 2 mins

  • 45 lakhs+ doctors trust M3 globally

  • Nonloggedininfinity icon
    Free & unlimited access to original articles and quizzes
  • Nonloggedinlock icon
    Secure: we never sell your data
This article is only available to members. Are you a doctor? Click here to signup for free.
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay